PD-1/PD-L1-IN-9 NEW
| Price | $55 | $82 | $136 |
| Package | 1mg | 2mg | 5mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-19 |
Product Details
| Product Name: PD-1/PD-L1-IN-9 | CAS No.: 2628506-54-5 |
| Purity: 99.37% | Supply Ability: 10g |
| Release date: 2024/11/19 |
Product Introduction
Bioactivity
| Name | PD-1/PD-L1-IN-9 |
| Description | PD-1/PD-L1-IN-9, with an IC50 of 3.8 nM, is a potent and orally active inhibitor of the PD-1/PD-L1 interaction. It enhances the immune cells' ability to kill tumor cells and demonstrates significant antitumor activity in vivo in a CT26 mouse model. |
| In vitro | PD-1/PD-L1-IN-9 (46.9-1500 nM; pretreated for 2 h) enhances the antitumor immunity of PBMCs against MDB-MB 231 cells in a dose-dependent manner, with an EC50 of approximately 100 nM[1]. |
| In vivo | PD-1/PD-L1-IN-9 (40-80 mg/kg; p.o. once a day for 2 weeks) inhibits tumor growth in a dose-dependent manner without causing body weight loss or mortality in mice. PD-1/PD-L1-IN-9 (3 mg/kg; a single i.v.) exhibits a half-life (t1/2=4.2 h), plasma clearance (Cl=11.5 L/h/kg), and Cmax (1233 ng/mL) in rats. PD-1/PD-L1-IN-9 (25 mg/kg; a single p.o.) shows moderate oral bioavailability (F=22%), half-life (t1/2=6.4 h), and Cmax (192 ng/mL) in rats[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 90 mg/mL (258.3 mM), Sonication is recommended. |
| Keywords | PD-1/PD-L1-IN-9 | PD1/PDL1IN9 | PD 1/PD L1 IN 9 |
| Inhibitors Related | LSD1-IN-24 | Sulfamethoxypyridazine | PD-1-IN-22 | BMS-202 | BMS-1166-N-piperidine-CO-N-piperazine dihydrochloride | IMMH 010 maleate | BMS-8 | LSD1-IN-27 | PD-1/PD-L1-IN-10 | BMS-1 | Tomivosertib | PD-L1-IN-3 |
| Related Compound Libraries | Bioactive Compound Library | Anti-Breast Cancer Compound Library | Anti-Ovarian Cancer Compound Library | Inhibitor Library | PPI Inhibitor Library | Immuno-Oncology Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library | Anti-Cancer Active Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $1980.00/50mg |
VIP1Y
|
TargetMol Chemicals Inc.
|
2024-10-28 | |
| $451.00/100μg |
VIP3Y
|
TargetMol Chemicals Inc.
|
2024-11-18 | |
| $0.00/1g |
VIP1Y
|
Wuhan Circle Star Chem-medical Technology Co.,Ltd
|
2025-01-08 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY